Literature DB >> 30430731

Interleukin 10 gene promoter polymorphisms (rs1800896, rs1800871 and rs1800872) and haplotypes are associated with the activity of systemic lupus erythematosus and IL10 levels in an Iranian population.

Saeed Mohammadi1, Marie Saghaeian Jazi2, Mojtaba Zare Ebrahimabad3, Farnaz Eghbalpour4, Nafiseh Abdolahi5, Alijan Tabarraei6, Yaghoub Yazdani7.   

Abstract

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with unknown aetiology. According to the role of interleukin 10 (IL10) in SLE pathogenesis, the genetic alterations in its promoter region could be associated with elevated IL10 levels and exacerbated disease. Here, we investigated the association of genotype and haplotype frequencies of three IL10 gene promoter polymorphisms with susceptibility to SLE, IL10 plasma levels and disease activity of patients in an Iranian population. A total of 116 SLE patients and 131 healthy subjects were enrolled. The PCR-RFLP technique was used to detect IL10 promoter genotypes at the positions of -1082 (G/A), -819 (C/T) and -592 (C/A) in association with IL10 plasma levels and SLEDAI scores. The GG genotype of -1082 polymorphism was associated with the increased risk of SLE [OR = 2.65, 95% CI (1.21-5.82), p-value = 0.046]. The CC genotype in -819 region was associated with SLE susceptibility [OR = 3.38, 95% CI (1.26-9.07), p-value = 0.034] and C allele was introduced as risk allele [OR = 1.86, 95% CI (1.15-3.01), p-value = 0.009] in this region. IL10 plasma levels were overexpressed in CC genotype carriers of -592 SNP and decreased in AA genotype carriers of -1082. IL10 was also increased in SLE patients with CGT (-592/-1082/-819) haplotype. The SLEDAI score was higher among CC genotype carriers at the position of -592 and TT genotype carriers at the region of -819. SLEDAI was also elevated among patients with CGC (-592/-1082/-819) and CAC (p = 0.011) haplotypes. The present study suggests that the IL10 -819(C/T), -1082(G/A) and -592(C/A) polymorphisms and the haplotypes are associated with SLE susceptibility, increased disease activity and elevated IL10 levels. While this is the first time to report such an association in an Iranian population, further studies are needed to confirm these findings.
© 2018 John Wiley & Sons Ltd.

Entities:  

Keywords:  haplotype; interleukin 10; polymorphism; promoter; systemic lupus erythematosus

Mesh:

Substances:

Year:  2018        PMID: 30430731     DOI: 10.1111/iji.12407

Source DB:  PubMed          Journal:  Int J Immunogenet        ISSN: 1744-3121            Impact factor:   1.466


  5 in total

1.  IL-10 Gene Polymorphisms and IL-10 Serum Levels in Patients with Multiple Sclerosis in Lithuania.

Authors:  Ugne Masilionyte; Greta Gedvilaite; Kriste Kaikaryte; Alvita Vilkeviciute; Loresa Kriauciuniene; Brigita Glebauskiene; Renata Balnyte; Rasa Liutkeviciene
Journal:  Brain Sci       Date:  2022-06-18

2.  Genetic Variants in Interleukin-10 Gene Association with Susceptibility and Cervical Cancer Development: A Case Control Study.

Authors:  Pushpendra D Pratap; Syed Tasleem Raza; Ghazala Zaidi; Shipra Kunwar; Sharique Ahmad; Mark Rector Charles; Ale Eba; Muneshwar Rajput
Journal:  Glob Med Genet       Date:  2022-02-25

Review 3.  Genetic and molecular biology of systemic lupus erythematosus among Iranian patients: an overview.

Authors:  Meisam Gachpazan; Iman Akhlaghipour; Hamid Reza Rahimi; Ehsan Saburi; Majid Mojarrad; Mohammad Reza Abbaszadegan; Meysam Moghbeli
Journal:  Auto Immun Highlights       Date:  2021-01-30

4.  Correlation between interleukin gene polymorphisms and current prevalence and mortality rates due to novel coronavirus disease 2019 (COVID-2019) in 23 countries.

Authors:  Lutfiye Karcioglu Batur; Nezih Hekim
Journal:  J Med Virol       Date:  2021-06-10       Impact factor: 20.693

5.  Impact of IL-10 gene polymorphisms and its interaction with environment on susceptibility to systemic lupus erythematosus.

Authors:  Gui-Hong Wang; Ting Zuo; Zheng-Cai Zuo
Journal:  Int J Immunopathol Pharmacol       Date:  2020 Jan-Dec       Impact factor: 3.219

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.